Kinnate Biopharma Inc (KNTE) Beta Value: Understanding the Market Risk

The 36-month beta value for KNTE is also noteworthy at 1.35. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

The public float for KNTE is 23.17M, and at present, short sellers hold a 2.01% of that float. The average trading volume of KNTE on April 02, 2024 was 380.12K shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

KNTE) stock’s latest price update

Kinnate Biopharma Inc (NASDAQ: KNTE)’s stock price has plunge by 0.00relation to previous closing price of 2.66. Nevertheless, the company has seen a 0.38% surge in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-02-28 that Kinnate Biopharma Inc. (KNTE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

KNTE’s Market Performance

KNTE’s stock has risen by 0.38% in the past week, with a monthly rise of 2.70% and a quarterly rise of 12.24%. The volatility ratio for the week is 1.31% while the volatility levels for the last 30 days are 1.46% for Kinnate Biopharma Inc The simple moving average for the last 20 days is 2.48% for KNTE stock, with a simple moving average of 16.85% for the last 200 days.

Analysts’ Opinion of KNTE

Many brokerage firms have already submitted their reports for KNTE stocks, with Stifel repeating the rating for KNTE by listing it as a “Hold.” The predicted price for KNTE in the upcoming period, according to Stifel is $11 based on the research report published on November 17, 2022 of the previous year 2022.

H.C. Wainwright, on the other hand, stated in their research note that they expect to see KNTE reach a price target of $33. The rating they have provided for KNTE stocks is “Buy” according to the report published on July 28th, 2022.

Jefferies gave a rating of “Buy” to KNTE, setting the target price at $46 in the report published on September 27th of the previous year.

KNTE Trading at 7.39% from the 50-Day Moving Average

After a stumble in the market that brought KNTE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.98% of loss for the given period.

Volatility was left at 1.46%, however, over the last 30 days, the volatility rate increased by 1.31%, as shares surge +2.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.09% upper at present.

During the last 5 trading sessions, KNTE rose by +0.19%, which changed the moving average for the period of 200-days by -15.98% in comparison to the 20-day moving average, which settled at $2.60. In addition, Kinnate Biopharma Inc saw 12.24% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at KNTE starting from Tananbaum James B., who purchase 1,780,000 shares at the price of $2.80 back on May 08 ’23. After this action, Tananbaum James B. now owns 3,525,957 shares of Kinnate Biopharma Inc, valued at $4,984,000 using the latest closing price.

Foresite Capital Management IV, the 10% Owner of Kinnate Biopharma Inc, purchase 1,780,000 shares at $2.80 during a trade that took place back on May 08 ’23, which means that Foresite Capital Management IV is holding 3,525,957 shares at $4,984,000 based on the most recent closing price.

Stock Fundamentals for KNTE

The total capital return value is set at -0.75. Equity return is now at value -58.86, with -49.80 for asset returns.

Based on Kinnate Biopharma Inc (KNTE), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -112.16. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is 70.63.

Currently, EBITDA for the company is -118.21 million with net debt to EBITDA at 0.45. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.19.


In summary, Kinnate Biopharma Inc (KNTE) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts